A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2008
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 23 Jan 2008 The expected completion date for this trial is now 1 Apr 2006.
- 20 Dec 2007 Status changed from in progress to completed.
- 18 Nov 2006 New trial record.